Can the prospectus of an index-tracking UCITS mention both replication methodologies (physical and synthetic replication)?

According to paragraph 28 of the guidelines, UCITS should disclose the identity of the entity(ies) to which the direct and indirect costs and fees are paid and indicate if these are related parties to the UCITS management company or the depositary. Where should this information be disclosed?

In some jurisdictions, UCITS management companies may also act as securities lending agents. In this case, what information should be provided to investors?

According to the guidelines, all revenues arising from efficient portfolio management techniques, net of direct and indirect operational costs, should be returned to the UCITS. Does this mean that securities lending agents should not be paid for their services?

In the case of umbrella UCITS, does the requirement to use the label “UCITS ETF” apply to both the umbrella level and the sub-fund level?